Mirikizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Mirikizumab
Monoclonal antibody
Type ?
Source Humanized (from mouse)
Target interleukin 23A
Clinical data
Synonyms LY3074828
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6380H9842N1686O2004S48
Molar mass 143.8 g/mol

Mirikizumab (LY3074828) (INN[1]) is a human monoclonal antibody designed for the treatment of autoimmune diseases.

This drug was developed by Eli Lilly and Co.[2]

References[edit]